Sichuan Biokin PharmaceuticalLtd Valuation

Is 688506 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688506 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688506's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688506's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688506?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 688506. This is calculated by dividing 688506's market cap by their current preferred multiple.
What is 688506's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥77.97b

688506 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	12.6x
Enterprise Value/EBITDA	17x
PEG Ratio	-0.2x

Price to Earnings Ratio vs Peers

How does 688506's PE Ratio compare to its peers?

The above table shows the PE ratio for 688506 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	23.8x
600196 Shanghai Fosun Pharmaceutical (Group)	36.9x	31.4%	CN¥61.0b
000999 China Resources Sanjiu Medical & Pharmaceutical	17.3x	10.1%	CN¥58.5b
000538 Yunnan Baiyao GroupLtd	22.7x	8.8%	CN¥101.0b
002422 Sichuan Kelun Pharmaceutical	18.2x	10.9%	CN¥51.9b
688506 Sichuan Biokin PharmaceuticalLtd	18.5x	-95.8%	CN¥78.0b

Price-To-Earnings vs Peers: 688506 is good value based on its Price-To-Earnings Ratio (18.5x) compared to the peer average (23.8x).

Price to Earnings Ratio vs Industry

How does 688506's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 688506 is good value based on its Price-To-Earnings Ratio (18.5x) compared to the CN Pharmaceuticals industry average (28.1x).

Price to Earnings Ratio vs Fair Ratio

What is 688506's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688506 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	18.5x
Fair PE Ratio	5.6x

Price-To-Earnings vs Fair Ratio: 688506 is expensive based on its Price-To-Earnings Ratio (18.5x) compared to the estimated Fair Price-To-Earnings Ratio (5.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.